Nivolumab is a fully-humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody that is FDA-approved to treat various cancers such as melanoma, NSCLC, RCC, and Hodgkin’s lymphoma [65]. This evidence concerns the gene PDCD1 and renal cell carcinoma.